Easom Andrea
Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, AR. USA.
Nephrol Nurs J. 2009 Sep-Oct;36(5):529-37, 553.
In healthy individuals, the body remains in an iron-balanced state. Iron intake and loss on a daily basis is minimal, and the majority of iron in the body is recycled. However, patients on hemodialysis may have an insufficient supply of iron available to the bone marrow for erythropoiesis, a condition known as iron-restricted erythropoiesis or inflammation-mediated reticuloendothelial blockade. This state may occur as a result of an inflammatory process and can limit the patient's ability to respond to erythropoiesis-stimulating agents (ESAs). Intravenous (IV) iron supplementation may be needed to overcome iron-restricted erythropoiesis and improve ESA response. This article focuses on the complex relationship among the three I's in anemia management: inflammation, iron-restricted erythropoiesis, and IV iron treatment.
在健康个体中,身体保持铁平衡状态。每日铁的摄入量和损失量极少,且体内大部分铁会被循环利用。然而,接受血液透析的患者可能骨髓中用于红细胞生成的铁供应不足,这种情况被称为铁限制红细胞生成或炎症介导的网状内皮细胞阻滞。这种状态可能是炎症过程的结果,并且会限制患者对促红细胞生成素(ESA)的反应能力。可能需要静脉补充铁剂来克服铁限制红细胞生成并改善ESA反应。本文重点关注贫血管理中三个“i”之间的复杂关系:炎症、铁限制红细胞生成和静脉铁治疗。